Transcription of part of 4-7 conference call posted by

New Post Public Reply Private Reply Replies (0) Message Board
Enjay
633
Transcription of part of 4-7 conference call posted by "Bridge" on YMB


Part 1 of 2. CD12 Results and Next Steps, from April 7 cc

In my efforts to make sense of the various analyses of CD12 results, I have transcribed part of the April 7th cc covering results and next steps. This is just a part of Nader’s opening remarks, no Q&A portion.

Minute 9:45

NP
Thank you, Dr. Kelly. Wow. This very sad news that you gave us, Dr. Kelly. With that explanation from Dr. Kelly, I believe I feel very safe on making this statement. In my humble opinion, there is no doubt that leronlimab will be part of the future of COVID-19 therapy. This opinion of mine is justified for me from the fact that:

-- with one trial in severe to critical population, we see data that indicated 82% 14-day survival benefit. Survival benefit was 82% with statistically significant p-value of .0233.

-- Change in clinical status for 14-days in the basis of ordinal scale: 400% better with a statistically significant p-value of .021.

-- 7% of these critically ill patients on leronlimab arm who were on invasive mechanical ventilator or ECMO walk out of the hospital within 14 days vs. zero in placebo arm. We could not evaluate a p-value for this scenario because since in the placebo arm zero patients walk out.

-- Hospital stay also shortened with, again, statistically significant p-value.

So these 4 strong items make me feel justified in my statement of saying in my humble opinion there is no doubt that leronlimab will be part of the future of COVID-19 therapy.

So this is 14-day results I am talking about.

-- So what happens to the patients in critically ill population in day 28, 21 days after the second injection of leronlimab? For 28-days results, our predefined primary endpoint or secondary endpoint, however you look at the data, leronlimab arm was better than placebo for all predefined primary endpoint and secondary endpoint. This is the basis of my excitement for future of leronlimab just in COVID-19. Other indications, I’ll get to it.

Now, there is an urgency that all of our shareholders have and that is why - that they want us to get EUA today. They want us to have EUA right now. However, no one is looking at how much product do we have. If we get EUA today, do we have enough product for one country? Just one country, any country. The answer is not if we are looking at a large country.

We only have 1.2 million vials, good for 300,000 treatments per patient -
600,000 doses which would treat 300,000 patients. As we have said in the past. We would like to dedicate more than half of this to Brazil if we are able to ensure EUA, and we already are talking about 100,000 vials perhaps dedicated to Philippines. We just announced that right after the market, so I’m sure everybody can see the press release. This is 100,000 vials for potential Compassionate Special Permit sales.

Meanwhile, we don’t have EUA anywhere in the world yet, even though we are very optimistic about getting an EUA with an additional small trial or maybe with our CD12 extra data that is coming in. So let’s talk about additional data, and how we are thinking about this task. [end of part 1]

CD12 Results and Next Steps, from April 7 cc, part 2

They won’t let me post this. I’ll try in sections before I give up

minute 14
We are currently exploring 3 paths to get the next study for COVID-19 completed and perhaps hit our primary endpoint like we did 3 years ago with a small HIV trial. The 3 options are this:

-- The first one: we can simply add more patients to the open-label of CD12 that we have, and recalculate the p-value until it is less than .05. Is this acceptable by regulatory agencies? I’m not sure. But we will be informing everyone about how this is shaping up. And so far, let me give you an update so you know how it is shaping up right now. Very good news today is we have 28-day mortality amongst our new 55 patients in open-arm data that is better in the whole mITT population and in the mITT population less than 65 or over 65 for our primary endpoint, 28-day mortality. And also the results so far in that is better in the 28-day mortality for critically ill population. And some of the results are MUCH better. For example, the mortality rate in the extension of CD12 right now in critically ill population is about 16.5, 16.7%, 16.7, about 17%. CD12, we had results of 28% in leronlimab, 37% in placebo. So the data is actually coming strong. That’s one option: get more data, recalculate, and see who likes the (inaudible).

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 173

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 50

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 74

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 21

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 43

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 229

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 44

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
NextPatient’s KLAS Marks Signal Specialty Workflow Fit

Updated Category News Views 35

A 93.3 score in healthcare software deserves a second look. Not a victory lap, not a drumroll—just a serious look at whether the product is solving an annoying, expensive operational problem for specialty practices. NextPatient’s recognition in the 2026 KLAS Emerging Solutions Top 20 Report lands in that category. The company placed in the top five for improving...

Continue Reading
Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 102

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Crypto Volatility and the REX Osprey XRP ETF

Updated Category News Views 134

Cryptocurrency Market Overview and Recent Trends Up until October, the cryptocurrency market was experiencing significant growth, with a total capitalization reaching approximately $4.28 trillion. This surge was driven by abundant liquidity and a heightened risk appetite among investors. However, the capital markets can be unpredictable, leading to a swift and adverse...

Continue Reading
Intelligent Bio Inks Global Deal to Expand Drug Testing Solutions

Updated Category News Views 126

Intelligent Bio Solutions Launches Global Distribution Pact Intelligent Bio Solutions Inc. (NASDAQ: INBS) has recently announced an exciting global distribution partnership with SMARTOX. This collaboration aims to introduce their innovative SmarTest Patch, a cutting-edge product designed for drug detection, to international markets beyond the U.S. and Canada, marking a...

Continue Reading
Discover the Long-Term Growth of American Financial Group AFG Stock

Updated Category News Views 148

The Remarkable Journey of American Financial Group (AFG) American Financial Group (AFG) has significantly outperformed the market over the past twenty years, showing an annualized return of 9.37%, which surpasses the market by 1.29%. With a market capitalization standing at an impressive $10.39 billion, AFG is a noteworthy player in the financial sector. Investment...

Continue Reading
Current Sentiment Analysis: Canaan Inc's Short Interest Insights

Updated Category News Views 352

Canaan Inc's Current Short Interest Overview Canaan Inc (NYSE: CAN) is witnessing changes in its stock sentiment, particularly regarding its short interest. Recent reports indicate that the short interest, expressed as a percentage of the float, has dropped by 8.14%. Currently, 36.17 million shares are sold short, representing 8.58% of the total shares available for...

Continue Reading
CalExitNow Push for CA GOP Ban & Sovereignty Talks

Updated Category News Views 296

California's Political Pot Stirs In the wild world of politics, California stands as a fiery beacon yet again. This time, CalExitNow, a fiery group championing California's self-determination, is taking aim at the state’s Republican Party. Reminds me of a stock under pressure—hesitate at your peril as the winds of change sweep through. Disqualification Petition: A...

Continue Reading